| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 4, 2025 9:00 A.M. |
| Form: | F-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
424B4 - PURPLE BIOTECH LTD. (0001614744) (Filer)
EFFECT - PURPLE BIOTECH LTD. (0001614744) (Filer)
REHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced public offering of an aggregate of 5,999,999 of the Company's American Depositary Shares (ADSs) (or pre-funded warrants in lieu thereof), with each ADS representing 200 ordinary shares, and short-term warrants to purchase up to 11,999,998 ADSs, at a combined public offering price of $1.00 per share (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short
$6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants REHOVOT, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the pricing of a public offering of an aggregate of 5,999,999 of the Company's American Depositary Shares (ADSs) (or pre-funded warrants in lieu thereof), with each ADS representing 200 ordinary shares, and short-term warrants to purchase up to 11,999,998 ADSs, at a combined public
Mt. Sinai Principal Investigator, Dr. Amir Horowitz, demonstrates tumor cell death induced by IM1240 in patient-derived treatment-resistant head and neck biopsies Synergistic effects were observed between the NK and the T cell engager arms of IM1240, a unique combination in the CAPTN-3 platform Analysis of approximately 26,000 human transcriptomes suggests that NKG2A expression is consistently accompanied by 5T4 in solid tissues, but not in blood, supporting the design of IM1240 IM1240, the first CAPTN-3 tri-specific antibody targeting 5T4, a novel tumor-associated antigen, advances toward first-in-human clinical trials, with IND submission planned for 2026 REHOVOT, Israel, Sept. 04, 2
Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the year and the three months ended December 31, 2022. "We are reporting our 2022 financial results which are in line with our plans," said Gil Efron, Chief Executive Officer of Purple Biotech. "Our end-of-y
REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was held in Lisbon, Portugal from June 16-19, 2025. "Purple's proprietary CAPTN-3 platform of T-cell engagers enables the creation of a large number of antibodies to different targets, and by capping the anti-CD3 a
Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at AACR Annual Meeting 2025; NT219 Phase 2 study in head and neck cancer on track to be initiated in First Half of 2025 CAPTN-3 differentiated T-cells and NK cells engagers tri-specific platform advances toward first-in-human clinical trials REHOVOT, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, annou
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, c
SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)
SC 13G - PURPLE BIOTECH LTD. (0001614744) (Subject)
SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)